Literature DB >> 12665803

Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.

Yoko Yamamoto1, Yasuo Tsutsumi, Yasuo Yoshioka, Toshihide Nishibata, Kyoko Kobayashi, Takayuki Okamoto, Yohei Mukai, Tomoe Shimizu, Shinsaku Nakagawa, Satoshi Nagata, Tadanori Mayumi.   

Abstract

Addition of polyethylene glycol to protein (PEGylation) to improve stability and other characteristics is mostly nonspecific and may occur at all lysine residues, some of which may be within or near an active site. Resultant PEGylated proteins are heterogeneous and can show markedly lower bioactivity. We attempted to develop a strategy for site-specific mono-PEGylation using tumor necrosis factor-alpha (TNF-alpha). We prepared phage libraries expressing TNF-alpha mutants in which all the lysine residues were replaced with other amino acids. A fully bioactive lysine-deficient mutant TNF-alpha (mTNF-alpha-Lys(-)) was isolated by panning against TNF-alpha-neutralizing antibody despite reports that some lysine residues were essential for its bioactivity. mTNF-alpha-Lys(-) was site-specifically mono-PEGylated at its N terminus. This mono-PEGylated mTNF-alpha-Lys(-), with superior molecular uniformity, showed higher bioactivity in vitro and greater antitumor therapeutic potency than randomly mono-PEGylated wild-type TNF-alpha. These results suggest the usefulness of the phage display system for creating functional mutant proteins and of our site-specific PEGylation approach.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665803     DOI: 10.1038/nbt812

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  29 in total

1.  Experimental evolution of a green fluorescent protein composed of 19 unique amino acids without tryptophan.

Authors:  Akio Kawahara-Kobayashi; Mitsuhiro Hitotsuyanagi; Kazuaki Amikura; Daisuke Kiga
Journal:  Orig Life Evol Biosph       Date:  2014-11-16       Impact factor: 1.950

2.  Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

Authors:  Mithun M Shenoi; Isabelle Iltis; Jeunghwan Choi; Nathan A Koonce; Gregory J Metzger; Robert J Griffin; John C Bischof
Journal:  Mol Pharm       Date:  2013-04-17       Impact factor: 4.939

3.  Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL.

Authors:  Arianna Gonelli; Oriano Radillo; Sara Drioli; Erika Rimondi; Paola Secchiero; Gian Maria Bonora
Journal:  Invest New Drugs       Date:  2010-12-02       Impact factor: 3.850

4.  Folate-polyethylene glycol conjugated near-infrared fluorescence probe with high targeting affinity and sensitivity for in vivo early tumor diagnosis.

Authors:  Fei Liu; Dawei Deng; Xinyang Chen; Zhiyu Qian; Samuel Achilefu; Yueqing Gu
Journal:  Mol Imaging Biol       Date:  2010-12       Impact factor: 3.488

5.  Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

Authors:  Jan Terje Andersen; Rikard Pehrson; Vladimir Tolmachev; Muluneh Bekele Daba; Lars Abrahmsén; Caroline Ekblad
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

6.  Impact of pro segments on the folding and function of human neutrophil alpha-defensins.

Authors:  Zhibin Wu; Xiangqun Li; Bryan Ericksen; Erik de Leeuw; Guozhang Zou; Pengyun Zeng; Cao Xie; Chong Li; Jacek Lubkowski; Wei-Yue Lu; Wuyuan Lu
Journal:  J Mol Biol       Date:  2007-02-22       Impact factor: 5.469

7.  PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.

Authors:  Emily E Reichard; Nisha Nanaware-Kharade; Guillermo A Gonzalez; Shraddha Thakkar; S Michael Owens; Eric C Peterson
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

8.  Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.

Authors:  Masaki Inoue; Yuta Tsuji; Chinatsu Yoshimine; Shota Enomoto; Yuki Morita; Natsuki Osaki; Masahiro Kunishige; Midori Miki; Shota Amano; Kanako Yamashita; Haruhiko Kamada; Yasuo Tsutsumi; Shin-Ichi Tsunoda
Journal:  J Biol Chem       Date:  2020-05-12       Impact factor: 5.157

Review 9.  Delivery of therapeutic proteins.

Authors:  Dipak S Pisal; Matthew P Kosloski; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

10.  Rapid antibody selection by mRNA display on a microfluidic chip.

Authors:  Noriko Tabata; Yuko Sakuma; Yumiko Honda; Nobuhide Doi; Hideaki Takashima; Etsuko Miyamoto-Sato; Hiroshi Yanagawa
Journal:  Nucleic Acids Res       Date:  2009-03-30       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.